Form 4: MIRA CEO Aminov Acquires 2.68M Shares Post-Acquisition

MIRA Pharmaceuticals CEO Erez Aminov acquired 2,685,456 restricted common shares as compensation for the company's acquisition of SKNY Pharmaceuticals, Inc.

Summary

• Erez Aminov, Chief Executive Officer and Director of MIRA Pharmaceuticals, Inc., acquired 2,685,456 shares of common stock.
• The transaction occurred on October 1, 2025, with a deemed execution date of October 1, 2025.
• These shares were issued as compensation for MIRA Pharmaceuticals, Inc.'s acquisition of SKNY Pharmaceuticals, Inc.
• Following this transaction, Aminov beneficially owns a total of 3,530,156 shares of MIRA common stock.

Sentiment

Score: 7

Explanation: The filing indicates an acquisition and significant equity compensation for the CEO, which generally signals strategic growth and alignment of management interests with shareholders. While not a direct financial performance report, these are typically positive indicators.

Positives

• The filing indicates MIRA Pharmaceuticals, Inc. completed an acquisition of SKNY Pharmaceuticals, Inc., suggesting strategic growth.
• Chief Executive Officer Erez Aminov received significant equity compensation, aligning his interests with long-term shareholder value.

Future Outlook

NA

Management Comments

• The acquisition of 2,685,456 restricted shares of common stock by CEO Erez Aminov represents compensation for MIRA Pharmaceuticals, Inc.'s acquisition of SKNY Pharmaceuticals, Inc.

Industry Context

This transaction reflects M&A activity within the pharmaceutical sector, where executive compensation often includes equity incentives tied to strategic growth initiatives like acquisitions. Such compensation structures aim to align management's financial interests with the successful integration and performance of acquired entities.

Stakeholder Impact

• Shareholders: Potential dilution from new share issuance, but also potential long-term value creation from the acquisition and aligned CEO incentives.
• Employees: Employees of SKNY Pharmaceuticals, Inc. are now part of MIRA Pharmaceuticals, Inc., implying integration efforts.

Next Steps

• Integration of SKNY Pharmaceuticals, Inc. into MIRA Pharmaceuticals, Inc.

Key Dates

Keywords

MIRA Pharmaceuticals, Erez Aminov, insider transaction, Form 4, CEO compensation, stock acquisition, SKNY Pharmaceuticals, restricted stock, beneficial ownership